FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307777306> ?p ?o ?g. }

• W4307777306 endingPage "1906" @default.
• W4307777306 startingPage "1891" @default.
• W4307777306 abstract "The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin has shown reductions in major adverse cardiac events similar to glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, evidence is limited about how these therapies compare regarding overall healthcare resource utilization and costs in routine clinical care.We conducted a comparative cohort study based on linked prospective healthcare databases for the entire population of Denmark during 2015-2018. We included 13,747 new users of empagliflozin and 13,249 new users of GLP-1RAs. Propensity scores were applied to balance potential confounders across the two treatment groups through inverse probability treatment weighting (IPTW). We assessed directly referable costs per person-year associated with healthcare resource utilization (inpatient, emergency room, and outpatient clinic hospital care, primary care health services, and prescription medication costs at pharmacies) among drug initiators while on-treatment.The two IPTW cohorts were well balanced at baseline (median age 61 years, 60% men, diabetes duration 6.7 years, 19% with pre-existing ischemic heart disease, 8% with pre-existing cerebrovascular disease), with similar healthcare costs in the previous year. During follow-up, average on-treatment costs per person-year were very similar among empagliflozin and GLP-1 RA initiators for the following services: inpatient hospitalizations (13,565 DKK versus 13,275 DKK), hospital outpatient clinic visits (12,007 DKK versus 12,152 DKK), emergency room visits (370 DKK versus 399 DKK), and primary care services (4108 DKK versus 4302 DKK). Total costs for any prescription drugs were clearly lower for empagliflozin initiators than for GLP-1 RA initiators (8946 DKK versus 14,029 DKK). In sum, overall healthcare costs on-treatment were lower for empagliflozin initiators (38,995 DKK per person-year) than for GLP-1RA initiators (44,157 DKK per person-year).In this nationwide population-based cohort study, average healthcare costs after drug initiation and while on treatment were lower for empagliflozin initiators than for GLP-1RAs initiators, driven by lower drug costs.The study protocol and analysis plan have been registered on the website of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) ( http://www.encepp.eu/encepp/viewResource.htm?id=37726 , first protocol registration 4 June 2019), and on clinicaltrials.gov ( https://clinicaltrials.gov/ct2/show/NCT03993132 , first posted 20 June 2019)." @default.
• W4307777306 created "2022-11-05" @default.
• W4307777306 creator A5019514522 @default.
• W4307777306 creator A5033040903 @default.
• W4307777306 creator A5039543133 @default.
• W4307777306 creator A5056029496 @default.
• W4307777306 creator A5058381294 @default.
• W4307777306 creator A5060869575 @default.
• W4307777306 creator A5067008257 @default.
• W4307777306 creator A5082520060 @default.
• W4307777306 creator A5090386574 @default.
• W4307777306 date "2022-10-31" @default.
• W4307777306 modified "2023-10-10" @default.
• W4307777306 title "Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark" @default.
• W4307777306 cites W1849521086 @default.
• W4307777306 cites W1978670003 @default.
• W4307777306 cites W2146264128 @default.
• W4307777306 cites W2155984875 @default.
• W4307777306 cites W2166269970 @default.
• W4307777306 cites W2219591537 @default.
• W4307777306 cites W2541013163 @default.
• W4307777306 cites W2603138125 @default.
• W4307777306 cites W2894567505 @default.
• W4307777306 cites W2894993577 @default.
• W4307777306 cites W2958564402 @default.
• W4307777306 cites W2982188023 @default.
• W4307777306 cites W3025861706 @default.
• W4307777306 cites W3119442730 @default.
• W4307777306 cites W3120821309 @default.
• W4307777306 cites W3165881452 @default.
• W4307777306 cites W3173421961 @default.
• W4307777306 cites W3190801097 @default.
• W4307777306 cites W3201795055 @default.
• W4307777306 cites W4200607853 @default.
• W4307777306 cites W4207035779 @default.
• W4307777306 cites W4213148026 @default.
• W4307777306 cites W4225264667 @default.
• W4307777306 cites W4238720908 @default.
• W4307777306 cites W4253996779 @default.
• W4307777306 doi "https://doi.org/10.1007/s13300-022-01323-y" @default.
• W4307777306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36315384" @default.
• W4307777306 hasPublicationYear "2022" @default.
• W4307777306 type Work @default.
• W4307777306 citedByCount "0" @default.
• W4307777306 crossrefType "journal-article" @default.
• W4307777306 hasAuthorship W4307777306A5019514522 @default.
• W4307777306 hasAuthorship W4307777306A5033040903 @default.
• W4307777306 hasAuthorship W4307777306A5039543133 @default.
• W4307777306 hasAuthorship W4307777306A5056029496 @default.
• W4307777306 hasAuthorship W4307777306A5058381294 @default.
• W4307777306 hasAuthorship W4307777306A5060869575 @default.
• W4307777306 hasAuthorship W4307777306A5067008257 @default.
• W4307777306 hasAuthorship W4307777306A5082520060 @default.
• W4307777306 hasAuthorship W4307777306A5090386574 @default.
• W4307777306 hasBestOaLocation W43077773061 @default.
• W4307777306 hasConcept C126322002 @default.
• W4307777306 hasConcept C134018914 @default.
• W4307777306 hasConcept C159110408 @default.
• W4307777306 hasConcept C160735492 @default.
• W4307777306 hasConcept C162324750 @default.
• W4307777306 hasConcept C17923572 @default.
• W4307777306 hasConcept C194828623 @default.
• W4307777306 hasConcept C2426938 @default.
• W4307777306 hasConcept C2775887513 @default.
• W4307777306 hasConcept C2777180221 @default.
• W4307777306 hasConcept C2780724011 @default.
• W4307777306 hasConcept C2908647359 @default.
• W4307777306 hasConcept C50522688 @default.
• W4307777306 hasConcept C555293320 @default.
• W4307777306 hasConcept C71924100 @default.
• W4307777306 hasConcept C98274493 @default.
• W4307777306 hasConcept C99454951 @default.
• W4307777306 hasConceptScore W4307777306C126322002 @default.
• W4307777306 hasConceptScore W4307777306C134018914 @default.
• W4307777306 hasConceptScore W4307777306C159110408 @default.
• W4307777306 hasConceptScore W4307777306C160735492 @default.
• W4307777306 hasConceptScore W4307777306C162324750 @default.
• W4307777306 hasConceptScore W4307777306C17923572 @default.
• W4307777306 hasConceptScore W4307777306C194828623 @default.
• W4307777306 hasConceptScore W4307777306C2426938 @default.
• W4307777306 hasConceptScore W4307777306C2775887513 @default.
• W4307777306 hasConceptScore W4307777306C2777180221 @default.
• W4307777306 hasConceptScore W4307777306C2780724011 @default.
• W4307777306 hasConceptScore W4307777306C2908647359 @default.
• W4307777306 hasConceptScore W4307777306C50522688 @default.
• W4307777306 hasConceptScore W4307777306C555293320 @default.
• W4307777306 hasConceptScore W4307777306C71924100 @default.
• W4307777306 hasConceptScore W4307777306C98274493 @default.
• W4307777306 hasConceptScore W4307777306C99454951 @default.
• W4307777306 hasFunder F4320310441 @default.
• W4307777306 hasIssue "11-12" @default.
• W4307777306 hasLocation W43077773061 @default.
• W4307777306 hasLocation W43077773062 @default.
• W4307777306 hasLocation W43077773063 @default.
• W4307777306 hasOpenAccess W4307777306 @default.
• W4307777306 hasPrimaryLocation W43077773061 @default.
• W4307777306 hasRelatedWork W2026095104 @default.
• W4307777306 hasRelatedWork W2285736578 @default.

• next